

SHORT TITLE: DECLARE TIMI 58

RESEARCH PROTOCOL TITLE: Dapagliflozin Effect on Cardiovascular Events

PRINCIPAL INVESTIGATOR: Dave Lewis, MD

RESEARCH SPONSOR: AstraZeneca

Clinical Trials.Gov Listing at:

<http://clinicaltrials.gov/ct2/show/NCT01730534?term=dapagliflozin&rank=33>

STUDY PURPOSE

Patients who have type 2 diabetes are at a higher risk to have cardiovascular (heart problems and stroke) conditions and/or events. The purpose of this study is to learn about the cardiovascular safety of Dapagliflozin (the investigational drug) when given with standard medications for type 2 diabetes in people at risk for cardiovascular events.

ELIGIBILITY CRITERIA FOR SUBJECTS

The subject must be 18 years of age or older.

The subject must have a diagnosis of Diabetes Mellitus Type II

The Subject must have at least one high risk factor for cardiovascular events.

SUBJECT PAYMENT

Subjects will be reimbursed \$50 for each completed study visit.

RESEARCH LOCATION AND CONTACT PERSON

Lynn Skatrud, RN, CCRC

Meriter Wisconsin Heart

2601 West Beltline Hwy.

Suite 200

Madison, WI 53713

PHONE: 608-417-2168